title: Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
authors.affiliation: Digestive Diseases Center, Medical University of South Carolina, 96 Jonathan Lucas Street, 210 Clinical Sciences Building, Charleston, South Carolina 29425, USA, agrawala@musc.edu
authors.forename: Amit
authors.initials: A
authors.lastname: Agrawal
authors.forename: Radu
authors.initials: R
authors.lastname: Tutuian
authors.forename: Amine
authors.initials: A
authors.lastname: Hila
authors.forename: Donald O
authors.initials: DO
authors.lastname: Castell
mesh_terms: D000328:Adult; D002243:Carbolines / Q000627:therapeutic use*; D015154:Esophageal Motility Disorders / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D000068581:Tadalafil; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
chemical_list: D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate